Adding olaparib to Radium 223 improve progression-free survival (PFS) in patients with bone mets (median 8.9 v 4.7 month) esp. in those who did not receive prior taxotere.
From our radiation oncology colleagues, this is a study showing that for high-risk bone metastases, those treated prophylactically with radiation were associated with lower rates of skeletal related events. High risk was defined as a bulky (>2cm) lesion in the hip, long bone lesions occupying one-third (1/3) to two-thirds (2/3) of the cortical thickness, or disease of the vertebral body of the junctional spine or posterior element involvement.
This article was recommended by Dr. Carrascosa. The study is promising, but the number of patients is small. Another thing to consider is the use of a bone enhancing agent (only 50% of patients had it on both arms). The authors recommended larger trials, which may help add a sub-analysis to assess the role of bone enhancing agents.